Adial Pharmaceuticals completes AD04 demonstration batch production By Investing.com

robot
Abstract generation in progress

Adial Pharmaceuticals announced the completion of a demonstration batch production for AD04, its investigational drug for Alcohol Use Disorder. This batch met specifications for the planned Phase 3 clinical trial and matched previous phase 2 results, allowing the company to proceed with clinical and registration batches. Despite the stock trading near its 52-week low, analysts have price targets ranging from $8 to $42.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin